Pleural Diseases Market Epidemiology Report | Drug Pipeline, Therapies, and Regional Outlook 2024-2034

According to the IMARC Group, the pleural diseases market size reached a value of US$ 2.7 Billion in 2024. Looking forward, the 7MM is expected to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034. This can be attributed to the emerging popularity of video-assisted thoracoscopic surgery owing to its several advantages over traditional open surgeries, such as minimal invasion, shorter hospital stays, reduced postoperative pain, etc.

Pleural diseases represent a group of medical conditions that affect the pleura, which is the thin membrane that lines the lungs and the inside of the chest cavity. The pleural diseases market is significantly growing due to the rising prevalence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and lung cancer, which often lead to complications. Besides this, the aging population, which is more susceptible to such conditions due to comorbidities, is contributing to increased demand for advanced diagnostic and therapeutic solutions, thereby catalyzing the pleural diseases market expansion.

Technological advancements in imaging modalities, such as ultrasound-guided thoracentesis and high-resolution computed tomography (HRCT), are enabling earlier and more accurate diagnosis of these illnesses. This is complemented by the development of minimally invasive procedures like video-assisted thoracoscopic surgery (VATS) and indwelling pleural catheters, which are improving patient outcomes and recovery times. Additionally, increased research into targeted therapies and immunotherapies, particularly for malignant pleural mesothelioma, which offers new treatment avenues, is also stimulating the pleural diseases market growth. Growing awareness campaigns by healthcare organizations about the importance of timely diagnosis and management of the conditions are driving patient engagement and treatment uptake. Furthermore, the rising integration of digital health tools, such as telemedicine and remote monitoring systems, which enhance patient follow-up and management, particularly for chronic conditions, is expected to bolster the pleural diseases market expansion in the coming years.

Request for a sample of this report: https://www.imarcgroup.com/pleural-diseases-market/requestsample

This report also provides a detailed analysis of the current pleural diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the pleural diseases market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Novatech
2. Lung Therapeutics
3. RS Oncology

Countries Covered

1. United States
2. Germany
3. France
4. United Kingdom
5. Italy
6. Spain
7. Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145